Drug developer Inotek is closing several international offices and selling its Israeli manufacturing plant in an effort to focus its resources on four of its main clinical and preclinical programs, the Beverly, MA-based firm announced today. The company also announced a host of changes to its management, including the resignation of CEO Andrew Salzman, and the termination of a collaboration with Genentech.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
